menu
    • menu
    [{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Pathogen-Reduced Plasma","moa":"Immune","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cerus Corporation \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Cerus Corporation \/ Cerus Corporation"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Pathogen Reduced Cryoprecipitated Fibrinogen","moa":"Fibrinogen","graph1":"Hematology","graph2":"Phase IV","graph3":"Cerus Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ Cerus Corporation","highestDevelopmentStatusID":"11","companyTruncated":"Cerus Corporation \/ Cerus Corporation"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"Intercept Treated Red Blood Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ BARDA"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Funding","leadProduct":"Pathogen Reduced Lyophilized Cryoprecipitate","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Cerus Corporation","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ US Department of Defense","highestDevelopmentStatusID":"1","companyTruncated":"Cerus Corporation \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Cerus Corporation

    Menu

    Cerus Corporation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Recipient : Weill Medical College of Cornell University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative ...

                            Details : Undisclosed

                            Product Name : Intercept Fibrinogen Complex

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            February 03, 2023

                            Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Recipient : Weill Medical College of Cornell University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : US Department of Defense

                            Deal Size : $9.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, L...

                            Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...

                            Product Name : LyoCryo

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            February 11, 2022

                            Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : US Department of Defense

                            Deal Size : $9.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pathogen-Reduced Plasma

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Recipient : Coalition for National Trauma Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Plasma Resuscitation Without Lung Injury

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Pathogen-Reduced Plasma

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Recipient : Coalition for National Trauma Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Intercept Treated Red Blood Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : BARDA

                            Deal Size : $214.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cerus Expands BARDA Funding by Additional $14M

                            Details : Funding boosts further evaluation of the INTERCEPT Blood System's effectiveness in inactivating SARS-CoV-2 in all three blood components beyond what has already been identified.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 20, 2020

                            Lead Product(s) : Intercept Treated Red Blood Cell

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : BARDA

                            Deal Size : $214.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous Apheresis Platelet Component

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 12, 2016

                            Lead Product(s) : Autologous Apheresis Platelet Component

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NONOXYNOL-9

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Tr...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 08, 2014

                            Lead Product(s) : NONOXYNOL-9

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Intercept Plasma

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Usi...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 20, 2014

                            Lead Product(s) : Intercept Plasma

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S-303

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 04, 2012

                            Lead Product(s) : S-303

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : S303 RBCs

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 30, 2012

                            Lead Product(s) : S303 RBCs

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            Cerus Corporation

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Red Blood Cell

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 22, 2012

                            Lead Product(s) : Red Blood Cell

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth